Bristol Myers Gets CHMP Backing for Opdualag in Advanced Melanoma

By Colin Kellaher

Bristol Myers Squibb Co. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of its cancer treatment Opdualag for certain advanced melanoma patients.

The New York biopharmaceutical company said the recommendation covers the first-line treatment of unresectable or metastatic melanoma in patients 12 years of age and older with tumor cell PD-L1 expression < 1%.

The European Commission, which generally follows CHMP's advice, will now review the recommendation.

The U.S. Food and Drug Administration in March approved Opdualag, a combination of Bristol's blockbuster cancer drug Opdivo and its LAG-3-blocking antibody relatlimab, for patients 12 and older with unresectable or metastatic melanoma, the most serious type of skin cancer.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

July 22, 2022 07:36 ET (11:36 GMT)

Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024